Literature DB >> 25877789

Endoluminal perforation of a magnetic antireflux device.

Margit Bauer1, Alexander Meining2, Michael Kranzfelder3, Alissa Jell3, Rebekka Schirren3, Dirk Wilhelm3, Helmut Friess3, Hubertus Feussner4.   

Abstract

BACKGROUND: The history of surgical antireflux treatment is coined by the search for better alternatives to Nissen fundoplication. Implantable devices are one option, beginning with the "Angelchik" prosthesis 30 years ago. However, this procedure was left soon because of the high rate of foreign body connected problems (migration, perforation). A modern approach is a magnetic sphincter augmentation device (LINX Reflux Management System, Torax Medical, Shoreview, MN, USA), a magnetic chain which is implanted laparoscopically. Advantages reported are simplicity to apply and good results in reflux control, with up to now only rare complication rates as reported in the literature (Lipham et al. in Dis Esophagus, 2014).
METHODS: We report one case of erosion of the esophagus by a LINX system resulting in severe dysphagia.
RESULTS: A complete endoluminal removal could be achieved by a prototype OTSC-clip remover. Complete remission could be achieved. The technique is presented in detail (video).
CONCLUSIONS: In principle, total endoscopic removal of the LINX device is feasible in case of major erosion.

Entities:  

Keywords:  Antireflux device; Erosion; Interventional endoscopy; LINX®

Mesh:

Year:  2015        PMID: 25877789     DOI: 10.1007/s00464-015-4145-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  8 in total

1.  Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial.

Authors:  Luigi Bonavina; Tom DeMeester; Paul Fockens; Daniel Dunn; Greta Saino; Davide Bona; John Lipham; Willem Bemelman; Robert A Ganz
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

2.  The LINX® reflux management system: confirmed safety and efficacy now at 4 years.

Authors:  John C Lipham; Tom R DeMeester; Robert A Ganz; Luigi Bonavina; Greta Saino; Daniel H Dunn; Paul Fockens; Willem Bemelman
Journal:  Surg Endosc       Date:  2012-04-27       Impact factor: 4.584

Review 3.  [The Angelchik prosthesis--intermediate term evaluation and results].

Authors:  J R Siewert; H Feussner
Journal:  Z Gastroenterol       Date:  1988-08       Impact factor: 2.000

4.  Vicryl-scarf-induced scarring around esophagogastric junction as treatment of esophageal reflux disease. An experimental study in the dog.

Authors:  H Feussner; O P Horvath; J R Siewert
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

5.  Mechanical effect of the Angelchik prosthesis on the competency of the gastric cardia: pathophysiologic implications and surgical perspectives.

Authors:  L Bonavina; T DeMeester; R Mason; H J Stein; H Feussner; A Evander
Journal:  Dis Esophagus       Date:  1997-04       Impact factor: 3.429

6.  Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease.

Authors:  J C Lipham; P A Taiganides; B E Louie; R A Ganz; T R DeMeester
Journal:  Dis Esophagus       Date:  2014-03-11       Impact factor: 3.429

7.  Esophageal sphincter device for gastroesophageal reflux disease.

Authors:  Robert A Ganz; Jeffrey H Peters; Santiago Horgan; Willem A Bemelman; Christy M Dunst; Steven A Edmundowicz; John C Lipham; James D Luketich; W Scott Melvin; Brant K Oelschlager; Steven C Schlack-Haerer; C Daniel Smith; Christopher C Smith; Dan Dunn; Paul A Taiganides
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

8.  LINX(®) Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux.

Authors:  Luigi Bonavina; Greta Saino; John C Lipham; Tom R Demeester
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

  8 in total
  8 in total

1.  SAGES technology and value assessment committee (TAVAC) safety and effectiveness analysis: LINX® reflux management system.

Authors:  Dana A Telem; Andrew S Wright; Paresh C Shah; Matthew M Hutter
Journal:  Surg Endosc       Date:  2017-08-25       Impact factor: 4.584

2.  Worldwide Experience with Erosion of the Magnetic Sphincter Augmentation Device.

Authors:  Evan T Alicuben; Reginald C W Bell; Blair A Jobe; F P Buckley; C Daniel Smith; Casey J Graybeal; John C Lipham
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

Review 3.  Revaluation of the efficacy of magnetic sphincter augmentation for treating gastroesophageal reflux disease.

Authors:  Hongke Zhang; Dinghui Dong; Zhengwen Liu; Shuixiang He; Liangshuo Hu; Yi Lv
Journal:  Surg Endosc       Date:  2015-12-10       Impact factor: 4.584

4.  Removing the magnetic sphincter augmentation device: operative management and outcomes.

Authors:  James M Tatum; Evan Alicuben; Nikolai Bildzukewicz; Kamran Samakar; Caitlin C Houghton; John C Lipham
Journal:  Surg Endosc       Date:  2018-11-01       Impact factor: 4.584

5.  Magnetic Sphincter Augmentation for Gastroesophageal Reflux at 5 Years: Final Results of a Pilot Study Show Long-Term Acid Reduction and Symptom Improvement.

Authors:  Greta Saino; Luigi Bonavina; John C Lipham; Daniel Dunn; Robert A Ganz
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2015-10-05       Impact factor: 1.878

Review 6.  Endoscopic Management of Gastroesophageal Reflux Disease: Revisited.

Authors:  Zaheer Nabi; D Nageshwar Reddy
Journal:  Clin Endosc       Date:  2016-09-30

Review 7.  Spotlight on the Linx™ Reflux Management System for the treatment of gastroesophageal reflux disease: evidence and research.

Authors:  Jonathan Zadeh; Anthony Andreoni; Daniela Treitl; Kfir Ben-David
Journal:  Med Devices (Auckl)       Date:  2018-08-31

Review 8.  Magnetic challenge against gastroesophageal reflux.

Authors:  Mauro Bortolotti
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.